| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Achlorhydria | D000126 | 1 associated lipids |
| Actinomycetales Infections | D000193 | 4 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Angina Pectoris | D000787 | 27 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Faghih R et al. | Synthesis and antibacterial activity of (9S)-9-dihydroclarithromycin. | 1990 | J. Antibiot. | pmid:2147921 |
| Perronne C et al. | Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. | 1990 | Antimicrob. Agents Chemother. | pmid:2171421 |
| Morimoto S et al. | Chemical modification of erythromycins. III. In vitro and in vivo antibacterial activities of new semisynthetic 6-O-methylerythromycins A, TE-031 (clarithromycin) and TE-032. | 1990 | J. Antibiot. | pmid:2139023 |
| Kohno Y et al. | Autobacteriographic studies of clarithromycin and erythromycin in mice. | 1990 | Antimicrob. Agents Chemother. | pmid:2140497 |
| Marchi E | Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. | 1990 | Curr Med Res Opin | pmid:2140546 |
| Scaglione F | Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. | 1990 | Curr Med Res Opin | pmid:2140547 |
| Morimoto S et al. | Chemical modification of erythromycins. VI. Structure and antibacterial activity of acid degradation products of 6-O-methylerythromycins A. | 1990 | J. Antibiot. | pmid:2141599 |
| Hardy DJ et al. | Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. | 1990 | Antimicrob. Agents Chemother. | pmid:2143642 |
| Cacciapuoti AF et al. | Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives. | 1990 | J. Antibiot. | pmid:2145254 |
| Adachi T et al. | Crystal and molecular structure of (14R)-14-hydroxy-6-O-methylerythromycin A. | 1989 | J. Antibiot. | pmid:2737946 |
| Gorzynski EA et al. | Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. | 1989 | Antimicrob. Agents Chemother. | pmid:2524998 |
| Fernandes PB et al. | New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. | 1989 | Antimicrob. Agents Chemother. | pmid:2523688 |
| Fernandes PB et al. | In vitro and in vivo activities of clarithromycin against Mycobacterium avium. | 1989 | Antimicrob. Agents Chemother. | pmid:2530933 |
| Kohno Y et al. | Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. | 1989 | Antimicrob. Agents Chemother. | pmid:2526615 |
| Tinel M et al. | Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. | 1989 | J. Pharmacol. Exp. Ther. | pmid:2527301 |
| Adachi T et al. | Hydroxylation and N-demethylation of clarithromycin (6-O-methylerythromycin A) by Mucor circinelloides. | 1989 | J. Antibiot. | pmid:2529234 |
| Naik S and Ruck R | In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. | 1989 | Antimicrob. Agents Chemother. | pmid:2817858 |
| Sasaki J et al. | Microbial transformation of 6-O-methylerythromycin derivatives. | 1988 | J. Antibiot. | pmid:2971032 |
| Adachi T et al. | 14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human. | 1988 | J. Antibiot. | pmid:2971033 |
| Waites KB et al. | In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. | 1988 | Antimicrob. Agents Chemother. | pmid:2973283 |
| Barry AL et al. | Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test. | 1988 | J. Clin. Microbiol. | pmid:2976773 |
| Chang HR and Pechère JC | In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. | 1988 | Antimicrob. Agents Chemother. | pmid:2837140 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Segreti J et al. | In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2952061 |
| Benson CA et al. | In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. | 1987 | Antimicrob. Agents Chemother. | pmid:2952063 |
| Barry AL et al. | In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. | 1987 | Antimicrob. Agents Chemother. | pmid:2952064 |
| Chin NX et al. | Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. | 1987 | Antimicrob. Agents Chemother. | pmid:2953303 |
| Bowie WR et al. | In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2953304 |
| Hanson CW et al. | Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). | 1987 | J. Clin. Microbiol. | pmid:2954995 |
| Floyd-Reising S et al. | In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. | 1987 | Antimicrob. Agents Chemother. | pmid:2955742 |
| Fernandes PB et al. | Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. | 1987 | Antimicrob. Agents Chemother. | pmid:2957954 |
| Fernandes PB et al. | In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. | 1986 | Antimicrob. Agents Chemother. | pmid:2949695 |
| Morimoto S et al. | Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. | 1984 | J. Antibiot. | pmid:6706855 |
| Pike VW et al. | Semi-automated preparation of a 11C-labelled antibiotic--[N-methyl-11C]erythromycin A lactobionate. | 1984 | Int J Appl Radiat Isot | pmid:6231252 |
| Zullo A et al. | Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. | Saudi J Gastroenterol | pmid:22249086 | |
| Dharmalingam S et al. | Relationship of plasmid profile with the antibiotic sensitivity pattern of Helicobacter pylori isolates from peptic ulcer disease patients in Chennai. | Indian J Med Microbiol | pmid:17643038 | |
| Can C et al. | Symmetrical drug-related intertriginous and flexural exanthema induced by two different antibiotics. | Allergol Immunopathol (Madr) | pmid:23253684 | |
| Siemens J et al. | Transport of pharmaceuticals in columns of a wastewater-irrigated Mexican clay soil. | J. Environ. Qual. | pmid:20830907 | |
| Iwańczak BM et al. | Assessment of Sequential and Standard Triple Therapy in Treatment of Helicobacter pylori Infection in Children Dependent on Bacteria Sensitivity to Antibiotics. | Adv Clin Exp Med | pmid:27629844 | |
| Hajiaghamohammadi AA et al. | To evaluate of the effect of adding licorice to the standard treatment regimen of Helicobacter pylori. | Braz J Infect Dis | pmid:27614124 | |
| Zhang SH et al. | The effect of virulence genotypes of on eradication therapy in children. | Saudi J Gastroenterol | pmid:29652033 | |
| pmid:11817788 | ||||
| Bermejo Vicedo T et al. | [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia]. | Farm Hosp | pmid:15012176 | |
| Chang NL et al. | Clarithromycin-Induced Torsades de Pointes. | Am J Ther | pmid:25057773 | |
| Alkim H et al. | Role of Bismuth in the Eradication of Helicobacter pylori. | Am J Ther | pmid:26808355 | |
| Dajani A et al. | Importance of Helicobacter pylori eradcation for maintenance of remission of drug associated peptic ulcer disease. | Saudi J Gastroenterol | pmid:19858579 | |
| Yamazhan T et al. | In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey. | Med Princ Pract | pmid:16220015 | |
| Melo-Cristino J et al. | The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004. | Rev Port Pneumol | pmid:16572254 | |
| Pachot JI et al. | Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. | J Pharm Pharm Sci | pmid:12753725 | |
| Chen YI and Fallone CA | A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: A Canadian study conducted in a 'real world' setting. | Can J Gastroenterol Hepatol | pmid:26301332 |